Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the american society for blood and marrow transplantation
Multiple sclerosis (MS) is a chronic, disabling, immune-mediated, central nervous system demyelinating and degenerative disease. Approved disease modifying therapies may be incompletely effective in some patients with highly active relapsing disease and high risk of disability. Immunoablative or myeloablative therapy followed by autologous hematopoietic cell transplantation (AHCT) has been investigated in retrospective studies, clinical trials, and meta-analyses/systematic reviews as an approach to address this unmet clinical need.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Jeffrey A. Cohen, Laura E. Baldassari, Harold L. Atkins, James D. Bowen, Christopher Bredeson, Paul A. Carpenter, John R. Corboy, Mark S. Freedman, Linda M. Griffith, Robert Lowsky, Navneet S. Majhail, Paolo A. Muraro, Richard A. Nash, Marcelo C. Pasquini Source Type: research
More News: Biology | Clinical Trials | Disability | Hematology | Multiple Sclerosis | Study | Transplants